DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/f90328/hepatitis_c_hcv) has announced the addition of the "Hepatitis C (HCV) Market Forecast & Drugs Pipeline Analysis to 2016" report to their offering.
Hepatitis C virus drug market is experiencing a dramatic near-term growth, by crossing US$ 6 Billion in 2011 and is expected to be more than double of its current figure by 2015. This robust growth will be driven primarily by the launch of novel premium-priced agents that will increase the size of the drug-treated population, mainly as a result of the re-treatment of prior non-responder patients.
ABOUT THIS REPORT
Renub Research report entitled Hepatitis C (HCV) Market Forecast & Drugs Pipeline Analysis to 2016 is an essential source of information and analysis on the global HCV market. The report identifies the key trends shaping and driving the global HCV market. The report also provides insight into the prevalent competitive landscape, launched HCV drugs present and future performance, yet to be launched HCV drugs forecast. Most importantly, the report provides valuable insight into the pipeline products within the global Hepatitis C sector.
What We Have Achieved in this Report
- Comprehensive situation analysis of the Global Hepatitis C drug market and its dynamics.
- Identifying all available drugs, pipeline drugs and their position in clinical trials and quantifying their current and future market potential.
- Providing a robust long range value forecast for all available drugs, pipeline drugs and their position in clinical trial.
- Providing an understanding of key drivers and restraints and their impact on current and future market scenario.
Competitive Landscape
This section covers the key facts about the major companies that play an important role in Hepatitis C drug market. The companies analyzed in this section are:
- Anadys Pharmaceuticals
- Merck
- Pharmasset
- Roche
- Vertex Pharmaceuticals
All the companies have been analyzed from two points of views:
1) Strength of the company in Hepatitis C drug market 2) Weakness of the company in Hepatitis C drug market
For more information, including full table of contents, please visit http://www.researchandmarkets.com/research/f90328/hepatitis_c_hcv
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
There are no comments yet